Menu
Search
|

Menu

Close
X

Bellerophon Therapeutics Inc BLPH.OQ (NASDAQ Stock Exchange Global Market)

2.22 USD
+0.02 (+0.91%)
As of Feb 16
chart
Previous Close 2.20
Open 2.22
Volume 6,623
3m Avg Volume 52,023
Today’s High 2.22
Today’s Low 2.16
52 Week High 2.71
52 Week Low 0.88
Shares Outstanding (mil) 35.51
Market Capitalization (mil) 55.04
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.933
FY16
-1.603
FY15
-3.862
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-187.88
14.43
Return on Equity (TTM)
vs sector
-359.90
16.13

EXECUTIVE LEADERSHIP

Jonathan Peacock
Chairman of the Board, President, Since 2016
Salary: $201,539.00
Bonus: $224,000.00
Fabian Tenenbaum
Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director, Since 2016
Salary: --
Bonus: --
Assaf Korner
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Martin Meglasson
Chief Scientific Officer, Vice President, Since 2014
Salary: $307,154.00
Bonus: $266,160.00
Reinilde Heyrman
Vice President, Chief Clinical Development Officer and Secretary, Since 2014
Salary: $366,808.00
Bonus: $288,720.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

184 Liberty Corner Rd Ste 302
WARREN   NJ   07059-6796

Phone: +1908.5744770

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.

SPONSORED STORIES